Loading…
← CockpitCompetitor Analysis › 2575.HK Xuanzhu Biopharmaceutical Co., Ltd. Class HOpen in the cockpit ↗

Xuanzhu Biopharmaceutical Co., Ltd. Class H2575.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Industrials›Miscellaneous Commercial Services
Momentum laggard 15
Mkt cap
$514M
US dollars, full cap
Free float
35%
of shares outstanding
$/day
$1.71M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-28.0 pp
WACC 6.1%
Hurdle
n/a
no reverse DCF
Close · HKDHK$7.70
1D-4.3%
1W-7.8%
1M-7.1%
3M-32.0%
6M-59.7%
YTD-89.1%
1Y-88.4%
ATR %8.1%
52w lowhigh92.0% off high

What Xuanzhu Biopharmaceutical does

Employees: 342

Xuanzhu Biopharmaceutical at a glance

Size Xuanzhu Biopharmaceutical (2575.HK) is a Hong Kong Industrials company (Miscellaneous Commercial Services) with a market value of $514M, the 740th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$7.70 on 18 Nov 2026.

Performance Over six months the shares fell 59.7%, against -11.8% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — lowest of 21 in its peer set.

Growth Revenue grew 237.2% over the last twelve months (peer median +9.0%); the operating margin is -186.7% (peer median 9.6%).

Valuation It trades at 29.0× enterprise value to sales against a peer median of 3.3× (most expensive of 20).

Capital Return on invested capital runs 28.0 points below its cost of capital (6.1% WACC).

Relative performance

40608010021 May 202621 Aug 202618 Nov 2026Peer median 912575.HK 40
Six months, rebased to 100: Xuanzhu Biopharmaceutical against the median of its 20 peers (local-currency closes).

Xuanzhu Biopharmaceutical financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$116MHK$56.1MHK$32.6MHK$32,045HK$0
Revenue growth—+72%+101,721%——
Gross profitHK$52.3MHK$21.8M-HK$12.6M-HK$35.5M-HK$30.2M
EBITDAn/a-HK$221M-HK$575M-HK$339M-HK$550M
Net income-HK$233M-HK$266M-HK$603M-HK$332M-HK$596M
Free cash flown/a-HK$224M-HK$105M-HK$130M-HK$501M
Capital expendituren/aHK$46.2MHK$87.0MHK$162MHK$194M
Total debtn/aHK$720,638HK$1.57MHK$18.8MHK$32.8M

Quarterly statements and history in the cockpit →

Xuanzhu Biopharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-10%0%300901301548300864429036360030321477301622MAPMYINDIABTS-B3265RST7722301456300071MHA30132534793012592575.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Xuanzhu Biopharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×10×20×30×30090130154830086442900030321477MAPMYINDIA30007130132534793012592575.HKRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Xuanzhu Biopharmaceutical is the large dot.

Xuanzhu Biopharmaceutical competitors and peer comparison

How Xuanzhu Biopharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Xuanzhu Biopharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure2575.HKPeer medianRank in peer set
1-month return-7.1%-3.4%9th lowest of 21
6-month return-59.7%-11.8%lowest of 21
Distance from 52-week high-92.0%-36.8%lowest of 21
Revenue growth (TTM)+237.2%+9.0%highest of 21
Operating margin-186.7%9.6%lowest of 21
EV / Sales29.0×3.3×most expensive of 20
ROIC minus cost of capital-28.0 pp+2.4 pp2nd lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Xuanzhu Biopharmaceutical 2575.HKHong Kong$514M-60%+237%-187%29.0×n/an/a
Zhejiang Zoenn Design 300901.SZChina$512M-24%+53%10%7.0×n/an/a
Hunan SUND Technological 301548.SZChina$518M-51%+23%21%3.5×16.7%+13.8%
Academy of Environmental Planning & Design Co., Ltd. Nanjing University 300864.SZChina$519M-7%+5%18%3.3×8.9%+10.6%
Prestige International 4290.TJapan$521M-2%+10%13%0.9×-12.4%+11.8%
Mitsubishi Research Institute 3636.TJapan$505M+11%+4%7%0.5×-8.6%+4.1%
Jiangsu Chuanzhiboke Education Technology 003032.SZChina$525M+27%+63%-7%5.8×n/an/a
Ocumension Therapeutics 1477.HKHong Kong$501M-24%+78%-13%3.5×n/an/a
Baotou INST Magnetic New Materials 301622.SZChina$501M-50%+3%-1%2.4×n/an/a
C.E. Info Systems MAPMYINDIA.NSIndia$499M-12%+3%31%8.3×31.7%+25.5%
BTS BTS-B.STSweden$499M+34%0%9%1.9×7.6%+13.0%
Winstek Semiconductor 3265.TWOTaiwan$499M-27%+15%20%3.3×n/an/a
Restore RST.LUnited Kingdom$531M+18%+8%13%2.1×6.0%+10.8%
LINE Pay Taiwan 7722.TWTaiwan$496M+1%+15%6%n/an/an/a
Qingdao Paguld Intelligent Manufacturing 301456.SZChina$494M-32%+29%13%3.2×n/an/a
FS Development Investment 300071.SZChina$536M-20%-41%-18%5.9×32.1%+1.0%
Weathernews 4825.TJapan$537M-12%+5%21%2.8×3.9%+5.4%
MHA MHA.LUnited Kingdom$493M-6%+12%15%1.5×-14.9%+30.6%
Shenzhen Manst Technology 301325.SZChina$493M-45%-52%-44%4.8×n/an/a
TKP 3479.TJapan$542M+23%+51%9%1.0×-3.4%+21.5%
Hunan Airbluer Environmental Protection Technology 301259.SZChina$543M-42%-43%-17%25.0×n/an/a

Questions

Which companies are Xuanzhu Biopharmaceutical's closest peers?
The cockpit's peer set: Zhejiang Zoenn Design (300901.SZ), Hunan SUND Technological (301548.SZ), Academy of Environmental Planning & Design Co., Ltd. Nanjing University (300864.SZ), Prestige International (4290.T), Mitsubishi Research Institute (3636.T), Jiangsu Chuanzhiboke Education Technology (003032.SZ), Ocumension Therapeutics (1477.HK), Baotou INST Magnetic New Materials (301622.SZ).
Is Xuanzhu Biopharmaceutical expensive compared with its peers?
On ev / sales it trades at 29.0× against a peer median of 3.3×, most expensive of 20 in its peer set.
How has Xuanzhu Biopharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -59.7% against -11.8% for the median peer; over one year -88.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.